Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists / 임상당뇨병
Journal of Korean Diabetes
;
: 252-259, 2015.
Article
Dans Coréen
| WPRIM
| ID: wpr-726854
ABSTRACT
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released from enteroendocrine L-cells upon nutrient absorption; it stimulates glucose-dependent insulin secretion from pancreatic betacells. GLP-1 has pleiotropic effects including deceleration of gastric emptying, decreased appetite, and increased satiety. Treatment with GLP-1 receptor agonists (GLP-1RAs) improves glycemic control in patients with type 2 diabetes without increasing the risk of hypoglycemia or weight gain. Current GLP-1RAs can be classified by their structure (exendin-4-based or human GLP-1-based), duration of action, and molecular size. Different GLP-1RAs exhibit different pharmacokinetics and pharmacodynamics. Herein we review the characteristics of available GLP-1RAs and discuss current issues such as insulin combination therapy and anti-obesity effects.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Appétit
/
Pharmacocinétique
/
Prise de poids
/
Décélération
/
Diabète de type 2
/
Absorption
/
Glucagon-like peptide 1
/
Incrétines
/
Récepteur du peptide-1 similaire au glucagon
/
Vidange gastrique
Limites du sujet:
Humains
langue:
Coréen
Texte intégral:
Journal of Korean Diabetes
Année:
2015
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS